Large Ovarian Fibroma With Torsion in a 17-Year-Old Patient: A Report of a Rare Case of Acute Surgical Abdomen. [PDF]
Xydias EM +7 more
europepmc +1 more source
What's New? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak +31 more
wiley +1 more source
Differential Mediating Roles of Immune-Inflammatory Cells in ≥HSIL Women: A Focus on HPV and CD4/CD8 or NLR. [PDF]
Tong Y +7 more
europepmc +1 more source
What's New? Circulating tumor cells (CTCs) are promising prognostic biomarkers for cancer. CTCs are sometimes very sparse; however, they present technical challenges for their enrichment from whole blood. Here, the authors tested the CTC enrichment capacity of a new nickel‐based filtration membrane and compared its efficacy to that of an FDA‐approved ...
Leonie F. Ott +26 more
wiley +1 more source
Correction: Zi et al. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells. <i>Int. J. Mol. Sci.</i> 2015, <i>16</i>, 27228-27251. [PDF]
Zi D +7 more
europepmc +1 more source
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source
Surgical Management of Ovarian Masses in Children: A Comparative Analysis by Pediatric Surgeons and Gynecologists at Two Academic Hospitals in Johannesburg. [PDF]
Mashaba NC +4 more
europepmc +1 more source
Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women
What's New? Since the introduction of the human papillomavirus (HPV) vaccine in 2006, vaccine‐type infections have declined markedly. As nonvaccine HPV types generally carry lower oncogenic potential, this shift warrants reevaluation of cervical screening regimens.
Mònica Ortega Llobet +10 more
wiley +1 more source

